301 related articles for article (PubMed ID: 28955654)
1. The role of novel immunotherapies in non-Hodgkin lymphoma.
Pishko A; Nasta SD
Transl Cancer Res; 2017 Feb; 6(1):93-103. PubMed ID: 28955654
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
5. Novel immunotherapies in lymphoid malignancies.
Batlevi CL; Matsuki E; Brentjens RJ; Younes A
Nat Rev Clin Oncol; 2016 Jan; 13(1):25-40. PubMed ID: 26525683
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in hematologic malignancies.
Kansara RR; Speziali C
Curr Oncol; 2020 Apr; 27(Suppl 2):S124-S131. PubMed ID: 32368182
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.
Buhmann R; Michael S; Juergen H; Horst L; Peschel C; Kolb HJ
J Transl Med; 2013 Jul; 11():160. PubMed ID: 23815981
[TBL] [Abstract][Full Text] [Related]
9. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM; Nowakowski GS; Wang Y
Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
[TBL] [Abstract][Full Text] [Related]
10. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
[TBL] [Abstract][Full Text] [Related]
11. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
12. Targeting non-Hodgkin lymphoma with blinatumomab.
Sanders S; Stewart DA
Expert Opin Biol Ther; 2017 Aug; 17(8):1013-1017. PubMed ID: 28532177
[TBL] [Abstract][Full Text] [Related]
13. [Development of mechanism-based targeted therapies for malignant lymphoma].
Rai S
Rinsho Ketsueki; 2020; 61(9):1266-1274. PubMed ID: 33162525
[TBL] [Abstract][Full Text] [Related]
14. Current Immunotherapy Approaches in Non-Hodgkin Lymphomas.
Pytlik R; Polgarova K; Karolova J; Klener P
Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33260966
[TBL] [Abstract][Full Text] [Related]
15. T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions.
Russler-Germain DA; Ghobadi A
Front Oncol; 2023; 13():1168622. PubMed ID: 37465110
[TBL] [Abstract][Full Text] [Related]
16. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
Abramson JS; Ghosh N; Smith SM
Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.
Tun AM; Ansell SM
Cancer Treat Rev; 2020 Aug; 88():102042. PubMed ID: 32521386
[TBL] [Abstract][Full Text] [Related]
18. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
Watkins MP; Bartlett NL
Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
[TBL] [Abstract][Full Text] [Related]
19. Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas.
Kasenda B; Kühnl A; Chau I
Expert Rev Hematol; 2016; 9(2):123-35. PubMed ID: 26581237
[TBL] [Abstract][Full Text] [Related]
20. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas.
Salvaris R; Ong J; Gregory GP
J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33946635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
